Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2026 08:30 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
March 05, 2026 07:00 ET | Source: https://immatics.com/

Immatics Announces Full Year 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug...
March 02, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
March 02, 2026 04:04 ET | Source: Research and Markets

Monoclonal Antibodies (mAbs) for Oncology Global Report 2026: A $228 Billion Market by 2030, Driven by Technological Advances, New Product Launches, Label Expansions, Increasing Prevalence

Dublin, March 02, 2026 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for monoclonal...
February 24, 2026 10:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
February 23, 2026 08:00 ET | Source: Alps Group Inc

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...
February 20, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
February 19, 2026 21:40 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Pricing of Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
February 19, 2026 10:48 ET | Source: Research and Markets

Claudin 18.2-Targeted Immunotherapy Pipeline Market Research Report 2026: an Up-to-date Competitor Evaluation in the Field of Therapy Candidates in Research and Development

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Claudin 18.2-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
February 19, 2026 10:46 ET | Source: Research and Markets

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Research Report 2026: More Than 20 Distinct Molecules Targeting the CD47-SIRP-a Pathway are in Clinical Development

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...